SOURCE: Wall Street News Alert

October 11, 2006 09:46 ET

IGTG Is on the Move: Begins Production of OxyView; Proprietary Technology to Be a Part of the $4 Billion Respiratory Therapy Device Market! October 11, 2006

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

WESTON, FL -- (MARKET WIRE) -- October 11, 2006 -- Wall Street News Alert's "stocks to watch" this morning are: Ingen Technologies Inc. (PINKSHEETS: IGTG), Pfizer (NYSE: PFE), Generex Biotechnology Corporation (NASDAQ: GNBT) and Boston Scientific Corp. (NYSE: BSX).

Ingen Technologies, Inc. (PINKSHEETS: IGTG) has released news! Yesterday after the stock markets closed, the company issued a press release announcing that it has begun production of its newest OxyView™ medical device; a proprietary technology to be a part of the $4 billion respiratory therapy device market.

Ingen's OxyView™ is a proprietary medical device that provides a visual signal of gas flow through a conduit. In particular, OxyView™ is a pneumatic flow meter that provides a visual cue, viewable with the human eye, as to the flow of gas through a cannula, which conventionally employs very low pressure and gas volume to the patient wearing it. The Company's proprietary device is adapted to be engaged between the nose or mouth-mounted cannula, where a compressed oxygen supply is delivered to the cannula through a flexible conduit. OxyView™ delivers an easily readable confirmation of actual continuous flow and volume of oxygen.

Continue to watch this company. According to the most current government reports and public statistical data, respiratory diseases are increasingly common ailments in both advanced and developing countries. With some 8-9% of Americans suffering from asthma, Chronic Obstruction Pulmonary Disease (COPD), bronchitis or other respiratory conditions, the high incidence and prevalence has translated into a large market for disposable respiratory products of $15 billion worldwide in 2005 with 70% related to asthma. Excluding asthma inhalers, the market for respiratory therapy devices still exceeds $4 billion and is expected to grow at 10% CAGR to over $6 billion by 2010. Further, the studies indicate an increase of patients with COPD, who are a prime population for the continuous use of oxygen in hospitals, long term care facilities and in the home. Many innovative drugs and medical devices are in the pipeline to treat respiratory diseases. The Company has targeted these markets for the sale of OxyView™.

Ingen Technologies CEO and Chairman Scott Sand said, "With the long-awaited introduction of our OxyView™ product and the resulting production, the growth potential for Ingen and the benefits to our shareholders are greatly improved. OxyView™ is FDA Registered and Classified, and sells for $14.95. We look forward to a successful introduction."

Ingen's OxyView™ application claims the benefit of U.S. Provisional Application Serial Number 60/780,980, filed on March 10, 2006. Patents have also been filed in Japan, Peoples Republic of China and in the European Communities in order to satisfy exclusive relationships with various over-seas distributors. Deliveries are scheduled for October 2006.

Prior to the latest press release, the stock closed yesterday at Four cents a share.

For an in-depth profile of Ingen Technologies, visit

To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit, where you may also sign up to receive free email alerts in advance of our press releases being issued.

In case you are not familiar with the company: Ingen Technologies, Inc. develops and markets cutting-edge medical technologies designed to increase accuracy of medical care and prevent unnecessary medical costs associated with today's healthcare industry. Ingen is a medical device manufacturer that owns two US patent(s), one US Patent Pending and three Foreign Patent Pending(s), several trademarks, intellectual property and proprietary medical products. The Company's Secure Balance™ product generates revenues for the company, and is a private-label product that includes a vestibular function testing system and balance therapy system that can identify and prevent fall injuries for the ever-growing elderly population.

The Company's flagship product is OxyAlert™, a second-generation design of the Company's BAFI™ product line that provides a low-oxygen safety warning device used on remote oxygen cylinders for patients, hospitals, commercial aircraft, military transport, and fire and safety equipment. OxyAlert™ technology uses digital sensing and RF frequency transfer so that caregivers can access a hand-held remote to monitor the actual oxygen level of any oxygen cylinder from a reasonable distance. OxyAlert™ increases safety and convenience for patients and clinical staff.

OxyView™, Patent Pending and FDA registered, is a pneumatic gauge that provides visual monitoring of oxygen flow-rate for patients (young and old) in the hospital, surgical room, outpatient therapy, nursing homes and emergency response facilities. This product enhances the safety, assurance and accuracy of patients being administered oxygen from any source. OxyView™ is a lightweight pneumatic gauge that is attached to the oxygen tubing just below the neck that informs nursing staff of the oxygen flow rate near the patient and the cannula; allowing instant information to inform a physician or technician of any leak or inaccuracy between the delivery source and the cannula.

Pfizer Inc. (NYSE: PFE) down 0.3% on 29.9 million shares traded.

Pfizer is committed to bringing meaningful improvement to the lives of people living with HIV/AIDS and those at risk around the world.

Generex Biotechnology Corporation (NASDAQ: GNBT) up 10.4% on 20.5 million shares traded.

Generex is engaged in the research and development of drug delivery systems and technologies.

Boston Scientific Corporation (NYSE: BSX) up 2.3% on 14.2 million shares traded.

Boston Scientific is a developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

Market Commentary:

"The National Retail Federation is predicting a good holiday selling season, a 5% increase over 2005. Sales were $457.4 billion last year and the average consumer spent $775 on holiday shopping. Only about 1 in 20 will have completed their gift buying by November 1," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at:

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 50 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at and select the "join now" button.

WSNA is a Platinum Sponsor of Quality Stocks. Quality Stocks tracks the stock picks of 150 Investment Newsletters every day and reports on their performance. For their free service, visit

*** It has come to the attention of Wall Street News Alert (WSNA), that various persons or companies distribute faxes bearing similar names to Wall Street News Alert. Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street.***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its Wall Street Enews brand. WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. WSCF has been compensated Fourteen Thousand Dollars for coverage of Ingen Technologies, Inc. (PINKSHEETS: IGTG), by a third party (National Financial Communications Corp.), who is non-affiliated and may hold a significant position in the stock, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact Information